

ONCOLYTICS BIOTECH INC
Form 6-K
November 18, 2009

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of November 2009

Commission File Number 000-31062

Oncolytics Biotech Inc.

(Translation of registrant's name into English)

Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Edgar Filing: ONCOLYTICS BIOTECH INC - Form 6-K

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 -

EXHIBIT
NUMBER DESCRIPTION

99.1 News Release Dated November 18, 2009 - Oncolytics Biotech® Inc. Announces Terms of Unit Offering

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc.
(Registrant)

Date: November 18, 2009

By:

/s/ Doug Ball

Doug Ball
Chief Financial Officer

0; 2,283 I Held in trust fbo Reporting Person's spouse. ⁽⁴⁾ Class A Common Stock 19 I Rankin Associates, IV, L.P. held by the Trust for the benefit of Reporting Person as general partner Class A Common Stock
14,567 I proportionate limited partnership interest in shares held by Rankin Associates I, L.P Class A Common Stock
35,628 I proportionate limited partnership interests in shares held by Rankin Associates II, L.P Class A
Common Stock 65,824 I proportionate limited partnership interest in shares held by Rankin Associates IV,
L.P Class A Common Stock 62 I interest in shares held by RAV held by Rankin Management, Inc. ("RMI")
Class A Common Stock 1,975 I proportionate interest in shares held by Rankin Management, Inc. ("RMI")
Class A Common Stock 132,073 I Reporting Person serves as Trustee of a Trust for the benefit of Claiborne
R. Rankin

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: ONCOLYTICS BIOTECH INC - Form 6-K

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock	(5)					(5)	(5)	Class A Common Stock	64,143
Class B Common Stock	(5)					(5)	(5)	Class A Common Stock	2,116
Class B Common Stock	(5)					(5)	(5)	Class A Common Stock	2,783
Class B Common Stock	(5)					(5)	(5)	Class A Common Stock	31
Class B Common Stock	(5)					(5)	(5)	Class A Common Stock	26,057
Class B Common Stock	(5)					(5)	(5)	Class A Common Stock	35,628

Class B Common Stock	<u>(5)</u>		<u>(5)</u>	<u>(5)</u>	Class A Common Stock	104,286
Class B Common Stock	<u>(5)</u>		<u>(5)</u>	<u>(5)</u>	Class A Common Stock	1,975
Class B Common Stock	<u>(5)</u>		<u>(5)</u>	<u>(5)</u>	Class A Common Stock	123,766
Class B Common Stock	<u>(5)</u>		<u>(5)</u>	<u>(5)</u>	Class A Common Stock	6,889
Class B Common Stock	<u>(5)</u>		<u>(5)</u>	<u>(5)</u>	Class A Common Stock	6,889
Class B Common Stock	<u>(5)</u>		<u>(5)</u>	<u>(5)</u>	Class A Common Stock	6,889

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
RANKIN CLAIBORNE R 5875 LANDERBROOK DRIVE MAYFIELD HEIGHTS, OH 44124	X			Member of a Group

Signatures

/s/ Suzanne S. Taylor,
attorney-in-fact

12/11/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares purchased pursuant to 10b5-1 plan
- (2) 2018-Dec-7-Weighted Average - Share Price represents average price between \$63.00 and \$64.00.
- (3) 2018-Dec-10-Weighted Average - Share Price represents average price between \$61.00 and \$61.95.
- (4) Reporting Person disclaims beneficial ownership of all such shares.
- (5) N/A
- (6) proportionate limited partnership interest in shares of Rankin Associates, IV, L.P. held by the Trust for the benefit of Reporting Person, as general partner.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.